BridgeBio Pharma (NASDAQ:BBIO) CAO Maricel Apuli Sells 2,000 Shares of Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CAO Maricel Apuli sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $72.85, for a total value of $145,700.00. Following the completion of the sale, the chief accounting officer directly owned 120,687 shares in the company, valued at approximately $8,792,047.95. This represents a 1.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Stock Performance

BridgeBio Pharma stock opened at $74.03 on Wednesday. The stock’s 50 day moving average is $70.00 and its 200 day moving average is $72.80. BridgeBio Pharma, Inc. has a twelve month low of $60.22 and a twelve month high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings data on Thursday, October 29th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.12. The company had revenue of $353.17 million for the quarter, compared to the consensus estimate of $293.47 million. The firm’s quarterly revenue was up 192.6% on a year-over-year basis. During the same period last year, the business earned ($0.95) EPS. On average, research analysts anticipate that BridgeBio Pharma, Inc. will post -2.59 EPS for the current year.

Hedge Funds Weigh In On BridgeBio Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Candriam S.C.A. raised its holdings in shares of BridgeBio Pharma by 133.9% during the third quarter. Candriam S.C.A. now owns 702,845 shares of the company’s stock valued at $46,416,000 after purchasing an additional 402,325 shares during the last quarter. Ethic Inc. bought a new position in BridgeBio Pharma during the third quarter valued at approximately $232,000. Pictet Asset Management Holding SA boosted its holdings in BridgeBio Pharma by 16.8% in the third quarter. Pictet Asset Management Holding SA now owns 1,690,829 shares of the company’s stock worth $111,290,000 after purchasing an additional 242,703 shares during the last quarter. Heritage Family Offices LLP purchased a new stake in BridgeBio Pharma in the third quarter worth approximately $39,000. Finally, Kestra Advisory Services LLC purchased a new stake in BridgeBio Pharma in the third quarter worth approximately $203,000. 99.85% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. UBS Group reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research report on Friday. Bank of America upped their price target on shares of BridgeBio Pharma from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Mizuho increased their price objective on shares of BridgeBio Pharma from $96.00 to $110.00 and gave the company an “outperform” rating in a research report on Tuesday, September 1st. Morgan Stanley raised their price objective on shares of BridgeBio Pharma from $87.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Finally, JPMorgan Chase & Co. raised their price objective on shares of BridgeBio Pharma from $100.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Nineteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $104.26.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes.

BridgeBio’s portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms.